SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): March 5, 2012
Senesco Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction
|(Commission File Number)
||(IRS Employer Identification No.)|
|721 Route 202-206, Suite 130, Bridgewater, NJ
|(Address of Principal Executive Offices)
(Registrant's telephone number,
including area code)
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|£||Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
|£||Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
|£||Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)).
|£||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).|
Item 8.01 Other Events.
On March 7, 2012, Senesco Technologies, Inc.
(the “Company”) issued a press release announcing that it has received Institutional Review Board approval and has
finalized a clinical trial research agreement with the West Virginia University Research Corporation of Morgantown, West Virginia
to evaluate SNS01-T, the Company’s lead therapeutic candidate, at the Mary Babb Randolph Cancer Center in the on-going Phase
1b/2a trial for the treatment of multiple myeloma.
The Mary Babb Randolph Cancer Center (MBRCC) is West Virginia’s premier cancer facility with a national
reputation of excellence in cancer treatment, prevention and research. Located in Morgantown, within the Robert C. Byrd Health
Sciences Center at West Virginia University School of Medicine, MBRCC is recognized by the American College of Surgeons Commission
on Cancer for providing the best in cancer care. A multidisciplinary team of physicians, researchers and other healthcare experts
work together to develop and implement the best possible individualized treatment plans, which include standard treatments and
exciting alternatives offered through clinical trials. The principal investigator in the study at West Virginia University is Dr.
In the study, patients are dosed twice-weekly
for 6 weeks followed by an observation period. The first group of three patients will receive 0.0125 mg/kg by intravenous infusion.
At the end of their 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher
dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively. The study
is an open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered
by intravenous infusion to a total of approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective
of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression
will be assessed using multiple well-established metrics including measurement of the monoclonal protein (M-protein). Patient dosing
in the study was initiated in November, 2011 at the Mayo Clinic in Rochester, Minnesota.
A copy of this press release is filed
as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01. Financial Statements
||Press Release of Senesco Technologies, Inc. dated March 7, 2012.|
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
||SENESCO TECHNOLOGIES, INC.|
|Dated: March 7, 2012
||/s/ Leslie J. Browne, Ph.D.
||Name: Leslie J. Browne, Ph.D.|
||Title: President and Chief Executive Officer|